Example: Heart Attack

Search clinical trials for: Lenalidomide

Total 921 results

NCT04497961

Not yet recruiting

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

Conditions: Multiple Myeloma
NCT04490707

Recruiting

Azacitidine Combined With Lenalidomide in AML

Conditions: Acute Myeloid Leukemia in Remission
NCT04483739

Not yet recruiting

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Conditions: Multiple Myeloma
NCT04481815

Recruiting

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Conditions: PCNSL
NCT04480099

Recruiting

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Conditions: Peripheral T-cell Lymphoma
NCT04460248

Not yet recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Conditions: Diffuse Large B Cell Lymphoma
NCT04446962

Not yet recruiting

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Conditions: Lymphoma, Large B-Cell, Diffuse; Central Nervous System Neoplasms, Primary
NCT04447027

Not yet recruiting

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Conditions: Relapsed/Refractory T-cell Malignancies; Cutaneous T-Cell Lymphoma; Mature T-cell Malignancies; Peripheral T-Cell Lymphoma
NCT04447716

Not yet recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Marginal Zone Lymphoma
NCT04435743

Recruiting

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Conditions: Non-hodgkin Lymphoma,B Cell
NCT04436107

Not yet recruiting

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04432402

Recruiting

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04432714

Recruiting

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Conditions: DLBCL; Untreated; MYC Gene Rearrangement
NCT04430894

Not yet recruiting

KRDI in Transplant-Eligible MM

Conditions: Multiple Myeloma
NCT04423926

Recruiting

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Conditions: PTCL, NOS; AITL; ALK- ALCL; Phase III-IV ALK+ ALCL; EATL
NCT04405167

Recruiting

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Conditions: Multiple Myeloma
NCT04404088

Recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma; Grade 3a Follicular Lymphoma
NCT04404283

Recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Conditions: Diffuse Large B-cell Lymphoma
NCT04396496

Not yet recruiting

Treatment of POEMS Syndrome With Daratumumab

Conditions: POEMS Syndrome
NCT04393363

Not yet recruiting

Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies

Conditions: Chemotherapy-induced Peripheral Neuropathy
NCT04361643

Not yet recruiting

Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial

Conditions: COVID-19
NCT04352205

Recruiting

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Conditions: Plasma Cell Myeloma; Renal Failure
NCT04348006

Recruiting

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

Conditions: Newly Diagnosed Multiple Myeloma
NCT04329130

Recruiting

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Conditions: Relapsed or Refractory Peripheral T-cell Lymphoma
NCT04328662

Recruiting

Ninlaro Intensive Drug Monitoring Protocol

Conditions: Multiple Myeloma; Neoplasms, Plasma Cell
NCT04326296

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Conditions: Colorectal Neoplasms
NCT04319601

Recruiting

Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Conditions: Angioimmunoblastic T-cell Lymphoma; Chemotherapy Effect; Chemotherapeutic Toxicity
NCT04309942

Recruiting

Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

Conditions: Multiple Myeloma
NCT04300803

Available

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Conditions: DLBCL
NCT04301076

Not yet recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Conditions: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection
NCT04298372

Recruiting

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Conditions: Amyloidosis Cardiac
NCT04288765

Recruiting

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04287660

Recruiting

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Conditions: Multiple Myeloma
NCT04283097

Recruiting

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Conditions: Hematological Malignancies
NCT04277845

Not yet recruiting

Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple.

Conditions: Multiple Myeloma
NCT04270409

Recruiting

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Conditions: Plasma Cell Myeloma
NCT04272775

Terminated

A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Conditions: Relapsed and/or Refractory Multiple Myeloma
NCT04268498

Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma
NCT04257448

Recruiting

Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

Conditions: Pancreas Cancer; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma
NCT04248595

Recruiting

Azacitidine Combined With Homoharringtonie in AML

Conditions: Acute Myeloid Leukemia
NCT04246086

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, Glofitamab + Lenalidomide, and Glofitamab + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma

Conditions: Follicular Lymphoma
NCT04243109

Terminated

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Conditions: Multiple Myeloma
NCT04234022

Not yet recruiting

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Conditions: Multiple Myeloma
NCT04231370

Recruiting

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

Conditions: NK/T Cell Lymphoma Nos
NCT04224493

Recruiting

Study in Subjects With Relapsed/Refractory Follicular Lymphoma

Conditions: Relapsed/Refractory Follicular Lymphoma
NCT04223661

Not yet recruiting

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

Conditions: Multiple Myeloma
NCT04217967

Recruiting

Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients

Conditions: Multiple Myeloma
NCT04214626

Recruiting

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04210791

Enrolling by invitation

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

Conditions: AL Amyloidosis; Plasma Cell Dyscrasia
NCT04196491

Recruiting

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Conditions: Multiple Myeloma

Search clinical trials for: Lenalidomide

Recent CRA jobs

Start-up CRA, Ukraine

Remote Site Monitor, Ukraine

Accounting Coordinator (Cambridge)

Associate Treasury Analyst (Cambridge)

Sr Safety Reporting Admin

Recruitment Coordinator (6-month)

CRA (Level I or II)

Clinical Trial Coord (Previuos called PA)

CRA (Level to be defined)

Assoc Biostatistician- Wayne PA